Shots:
- Axsome has entered into an asset purchase agreement with Takeda for TAK-063 (balipodect), with an intention to develop it for treating schizophrenia & Tourette syndrome (P-III trial-enabling activities for schizophrenia to begin in 2026)
- As per the deal, Axsome gains global rights to develop, manufacture, & commercialize TAK-063, while Takeda receives an upfront payment, & development, regulatory, & commercial milestone payments for the first two indications, plus royalties on global net sales
- Balipodect is a PDE10A inhibitor, which completed the 164-patient P-II PoC trial in schizophrenia, & showed favorable safety & tolerability profile in clinical studies in over 360 individuals to date
Ref: Globenewswire | Image: Axsome & Takeda |Press Release
Related News: Takeda Presents P-III (LATITUDE) Studies Data on Zasocitinib in Plaque Psoriasis at AAD 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
